In a nutshell This study aimed to investigate the GIMEMA LAL-1308 treatment protocol in young patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. This study concluded that this treatment protocol was safe and effective for these patients. Some background Adolescents and young adults...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of the combination of ivosidenib (Tibsovo) and azacitidine (Vidaza) in patients with acute myeloid leukemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutation (permanent change). This study concluded that this combination was well tolerated and...
Read More
In a nutshell This study aimed to compare outcomes of salvage chemotherapy for patients with relapsed or refractory acute myeloid leukemia. This study concluded that the CLAG-M regimen (cladribine, cytarabine, filgrastim, and mitoxantrone) followed by transplant is a suitable salvage treatment for these patients. Some...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of C-CAG including cladribine (Leustatin), granulocyte colony-stimulating factor (G-CSF, Neupogen), cytarabine (Cytosar-U), and aclarubicin (Aclacinon) in patients with relapsed/refractory (r/r) acute myeloid leukemia (AML). This study...
Read More
In a nutshell This trial is aiming to examine the effectiveness of zanubrutinib (Brukinsa) in combination with rituximab (Rituxan) to treat chronic lymphocytic leukemia (CLL). The main outcome to be measured is the number of patients who achieve the reduction or disappearance of their CLL. This trial is being carried out in Texas, the...
Read More
In a nutshell This study aimed to investigate if postinduction central nervous system (CNS; brain and spine) protection with intrathecal (injection into the spine) triple therapy (ITT) would improve the outcomes for pediatric patients with acute lymphoblastic leukemia (ALL) when compared to intrathecal methotrexate (MTX; Otrexup)...
Read More
In a nutshell The study evaluated outcomes of combining ofatumumab (Arzerra) with hyper-CVAD chemotherapy in patients with Philadelphia chromosome (Ph)-negative CD20-positive B-cell acute lymphoblastic leukemia (B-ALL). The authors found that the combination was safe and effective in such patients. Some background Philadelphia chromosome (Ph) is a...
Read More
In a nutshell This trial is comparing the effectiveness of a combined regimen of venetoclax (Venclexta) and obinutuzumab (Gazyva) or VEN-G to an existing drug regimen of fludarabine (Fludara), cyclophosphamide (Cytoxan), and rituximab (Rituxan) or FCR, or bendamustine (Treanda) and rituximab...
Read More
In a nutshell This study aimed to investigate the relationship between time from diagnosis to treatment start and outcomes for patients with acute myeloid leukemia. This study concluded that time from diagnosis to treatment is not related to survival in these patients. Some background Untreated acute myeloid leukemia...
Read More
In a nutshell This study aimed to compare the safety and effectiveness of bendamustine–rituximab (BR) and chlorambucil–rituximab (Chl-R) as a front-line treatment in older patients with chronic lymphocytic leukemia (CLL). This study concluded that both treatments are good options for these...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of combining daunorubicin (Cerubidine) and cytarabine (Cytosar-U) compared to idarubicin (Idamycin) and cytarabine as induction treatment for patients with acute myeloid leukemia. This study concluded that the idarubicin and cytarabine combination...
Read More
In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was safe and effective as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia. This study concluded that acalabrutinib was safe and effective in these patients. Some background Acalabrutinib is commonly...
Read More
